Results 111 to 120 of about 159,586 (333)

OCTN2 Activates a Non‐Canonical Carnitine Metabolic Pathway to Promote MASH‐HCC Progression and Immunotherapy Resistance

open access: yesAdvanced Science, EarlyView.
In non‐MASH‐HCC, L‐carnitine promotes tumor progression primarily through its classical role in enhancing fatty acid oxidation (FAO). However, in MASH‐HCC, where FAO is markedly suppressed, L‐carnitine shifts from this canonical function to serve instead as an intracellular acetyl group buffer.
Chuqi Xia   +11 more
wiley   +1 more source

Immune Responses to Tissue-Restricted Nonmajor Histocompatibility Complex Antigens in Allograft Rejection

open access: yesJournal of Immunology Research, 2017
Chronic diseases that result in end-stage organ damage cause inflammation, which can reveal sequestered self-antigens (SAgs) in that organ and trigger autoimmunity. The thymus gland deletes self-reactive T-cells against ubiquitously expressed SAgs, while
Ankit Bharat, T. Mohanakumar
doaj   +1 more source

Minor histocompatibility antigens [PDF]

open access: yesBlood, 1990
C, Perreault   +5 more
openaire   +3 more sources

Induction of Heme Oxygenase-1 and Major Histocompatibility Complex Antigens in Transient Forebrain Ischemia [PDF]

open access: bronze, 1998
Yasuji Matsuoka   +5 more
openalex   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

open access: yesAdvanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang   +7 more
wiley   +1 more source

Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang   +7 more
wiley   +1 more source

Cellular Identity Crisis: RD3 Loss Fuels Plasticity and Immune Silence in Progressive Neuroblastoma

open access: yesAdvanced Science, EarlyView.
Researchers discovered that therapy‐induced loss of RD3 protein in neuroblastoma triggers a dangerous shift: cancer cells become more stem‐like, invasive, and resistant to treatment while evading immune detection. RD3 loss suppresses antigen presentation and boosts immune checkpoints, creating an immune‐silent environment.
Poorvi Subramanian   +7 more
wiley   +1 more source

Programmable Antigen‐Specific Immunity via Self‐Adjuvanting Nanovaccines Co‐Delivering Immune Modulators

open access: yesAngewandte Chemie, EarlyView.
The self‐adjuvanting vaccine—comprising a covalent conjugate of antigen and adjuvant—was formulated into cationic lipid nanoparticles smaller than 100 nm to facilitate uptake by immune cells, with supplemental adjuvants incorporated to modulate immune responses.
Keita Ito   +9 more
wiley   +2 more sources

Home - About - Disclaimer - Privacy